Engineered T Cell Receptor for Cancer Immunotherapy

Among therapeutic strategies in cancer immunotherapy, involving immune-modulating antibodies, cancer vaccine or adoptive T cell transfer, T cells has been attractive target due to their cytotoxicity toward tumor cells and tumor antigen-specific binding of receptors.Taking advantage of exclusive properties of T cells, chimeric antigen receptor (CAR)-T and T cell receptor (TCR)-T cells were generated by genetic edition of their receptors, which led an improvement in specificity and effectiveness of the T cell therapy.Adoptive cell transfer of CAR-T cells has been successful for the treatment of hematological malignancies.To expand T cell therapy to solid tumors, T cells are modified to express defined TCR targeting tumor associated antigen (TAA), which is called TCR-T therapy.Here in, this review discusses anti-tumor T cell therapies with focus on engineered TCR-T cell therapy.We describe features of TCR-T cell therapy, and clinical application of TCR-T cell therapy to non-hematological malignancies.